Systemic therapy in retroperitoneal sarcoma management
Date
2018ISSN
1096-9098Source
Journal of Surgical OncologyVolume
117Issue
1Pages
87-92Google Scholar check
Metadata
Show full item recordAbstract
There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas comprising liposarcomas and leiomyosarcomas are by and large chemotherapy insensitive. There is an urgent need for more efficacious systemic therapies in the management of early and advanced stage retroperitoneal sarcomas.